IP Library Granted Patent US 10,077,249
Granted Patent B2
US 10,077,249 · App. 15/593,198 · Granted Sep 18, 2018

Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

Inventors: Zhe Li (San Diego, CA); Nathan Guz (Half Moon Bay, CA); Yiyang Shao (Beijing, CN); Julieana Cocuz (Neutraubling, DE); Markus Frieser (Maxhuette-Haidhof, DE); George Petros Yiannikouros (Florence, SC); Liang Liao (South San Francisco, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D401/04C07C47/575C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,077,249
App. No.
15/593,198
Granted
Sep 18, 2018
Kind
B2
Abstract

Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases it oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

Claims (50)

1. A process of synthesizing Compound (I):

the process comprising:

Step (i): treating a compound of formula (2):

wherein each R is independently —CH(CH 2 R 1 )—OR 2 or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl; and wherein each R 1 is independently hydrogen or alkyl, and each R 2 is independently alkyl;

with an acid to provide compound (1):

Step (ii): reacting compound (1) with a compound of formula (3):

wherein LG is a leaving group under alkylation reacting conditions to provide Compound (I); and optionally

Step (iii): crystallizing Compound (I) from Step (ii) from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C.

2. The process of claim 1 further comprising formylating a compound of formula (4):

to provide the compound of formula (2):

wherein each

R in compound of formulae (2) and (4) is —CH(CH 2 R 1 )—OR 2 or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl;

R 1 is hydrogen or alkyl, and

R 2 is alkyl.

3. The process of claim 2 further comprising reacting compound (5):

with a vinyl ether of formula CHR 1 ═CHOR 2 (wherein R 1 is hydrogen or alkyl and R 2 is alkyl), or 3,4-dihydro-2H-pyran optionally substituted with one, two or three alkyl, in the presence of a weak acid to provide the compound of formula (4):

wherein each R is —CH(CH 2 R 1 )—OR 2 (where is hydrogen or alkyl and R 2 is alkyl) or tetrahydropyran-2-yl optionally substituted with one, two, or three alkyl.

4. The process of claim 3 wherein compound (4) is treated in situ with a formylating agent to provide compound (2).

5. The process of claim 4 wherein compound (2) is treated in situ with an acid to provide compound (1).

6. The process of claim 1 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

7. The process of claim 4 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

8. The process of claim 5 wherein Compound (I) is crystallized from heptane and methyl tert-butyl ether at 45° C. +/−5° C. to 55° C. +/−5° C. to give Compound (I) in substantially pure Form II characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 13.37°, 14.37°, 19.95° or 23.92° 2θ (each ±0.2° 2θ).

9. The process of claim 6 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

10. The process of claim 7 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

11. The process of claim 8 wherein Compound (I) is crystallized at 45° C. to 55° C. to give Compound (I) wherein at least 95% by weight of Compound (I) is Form II.

12. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 and the acid for removal of the R groups is an inorganic acid.

13. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

14. The process of claim 3 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

15. The process of claim 4 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

16. The process of claim 5 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

17. The process of claim 6 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

18. The process of claim 7 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

19. The process of claim 8 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NO.

20. The process of claim 9 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

21. The process of claim 10 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

22. The process of claim 11 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI.

23. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

24. The process of claim 4 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

25. The process of claim 5 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

26. The process of claim 6 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

27. The process of claim 7 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

28. The process of claim 8 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

29. The process of claim 9 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

30. The process of claim 10 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro, in step (ii), and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

31. The process of claim 11 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , LG is chloro, in step (ii), and the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 50° C. to give substantially pure Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

32. The process of claim 1 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , the acid for the removal of R group is hydrochloric acid, LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 46° C. to give Compound (I) that comprises at least 95% by weight Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.220 2θ).

33. The process of claim 4 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , the acid for the removal of R group is hydrochloric acid, LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 46° C. to give Compound (I) that comprises at least 95% by weight Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

34. The process of claim 5 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , the acid for the removal of R group is hydrochloric acid, LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 46° C. to give Compound (I) that comprises at least 95% by weight Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

35. The process of claim 7 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , the acid for the removal of R group is hydrochloric acid, the weak acid is pyridinium tosylate, the formylating agent is n-BuLi and DMF, LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 46° C. to give Compound (I) that comprises at least 95% by weight Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

36. The process of claim 8 wherein R is —CH(CH 3 )—O—CH 2 CH 3 , the acid for the removal of R group is hydrochloric acid, the weak acid is pyridinium tosylate, the formylating agent is n-BuLi and DMF, LG is chloro and, in step (ii), the alkylation reaction is carried out in N-methyl-2-pyrrolidinone in the presence of sodium bicarbonate and a catalytic amount of NaI and Compound (I) is crystallized from the reaction mixture by addition of water at 40° C. to 46° C. to give Compound (I) that comprises at least 95% by weight Form I characterized by an XRPD pattern comprising an X-ray powder diffraction peak (Cu Kα radiation) at one or more of 12.82°, 15.74°, 16.03°, 16.63°, 17.60°, 25.14°, 25.82° and 26.44° 2θ (each ±0.2° 2θ).

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: LI, ZHE; GUZ, NATHAN; LIAO, LIANG
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 044137/0768 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: COCUZ, JULIEANA; FRIESER, MARKUS; YIANNIKOUROS, GEORGE PETROS
To: PATHEON REGENSBURG GMBH
Reel/Frame 044137/0918 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: SHAO, YIYANG
To: PHARMARON, INC.
Reel/Frame 044137/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: PHARMARON, INC.
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 044137/0841 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2017
From: PATHEON REGENSBURG GMBH
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 044137/0902 →
Continuity (2)
Provisional Application 62335583 · May 12, 2016
Related Publication 20170327484A1 · Nov 16, 2017